Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish pharmaceutical firm Moberg Pharma has extended its distribution agreement with Berlin-Chemie, a German subsidiary of the MENARINI Group, granting exclusive rights to market and sell Emtrix in Russia and Ukraine.
Subscribe to our email newsletter
The new agreement builds on an existing collaboration between the two parties, which resulted in a successful launch of Emtrix in Italy as well as the expansion to China and Southeast Asia where product launches have been initiated.
The company said that the rights to Emtrix in Russia were released from a previous distribution agreement with Meda but the product was not launched in Russia under that deal.
Moberg Pharma CEO Peter Wolpert said: "I am very pleased to expand our collaboration with the Menarini Group through this agreement with Berlin-Chemie, a leading marketer in Eastern Europe. The Russian market has significant long-term potential for Moberg’s products."
Berlin-Chemie International Division COO Michael Sirotovich said: "We look forward to introducing Emtrix to consumers in Russia.
"The product has potential to contribute strongly to our expansion within the Consumer Health market, as it provides rapid relief for a large segment of patients suffering from nail fungus."
Emtrix is a prescription-free, over-the-counter (OTC) product used for the treatment of nail disease.
The drug is sold under the names Kerasal Nail, Naloc/Nalox and Emtrix, and its safety and efficacy have been shown in several clinical studies including more than 600 patients.